RxDoctor Payments Data

Renee Palta, DO

Gastroenterology · Whittier, CANPI 1497910251

Payments from drug & device makers

$3,383in general payments, 2019–2025

Across 140 payments — averaging $24.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$570
  • Ardelyx, Inc.$293
  • Phathom Pharmaceuticals, Inc.$240
  • Johnson & Johnson$220
  • Madrigal Pharmaceuticals$214
  • plus $785 from 12 others

What the payments were for

  • Food & beverage$3,22895%
  • Education$1555%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,383 in reported general payments places this provider in the 55th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$93,334
Medicare patients
296
Services billed
646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$90,734
XifaxanRifaximin20$62,873
LinzessLinaclotide70$59,958
Mesalamine16$9,936
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates142$8,203
Ursodiol23$7,317
Lubiprostone47$5,281
Dexlansoprazole DrDexlansoprazole13$4,797
Omeprazole338$4,629
Sucralfate41$4,411
Pantoprazole Sodium145$2,079
Cholestyramine LightCholestyramine13$1,632
Lansoprazole44$1,433
Dicyclomine Hcl61$1,180
Esomeprazole Magnesium14$867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$75$62,87320 claims
AbbVieLinzess$1,061$59,95870 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →